XNAS:SGNT Insider Activity 3 Filing - 8/30/2012

Effective Date 8/30/2012

XNAS:SGNT (): Fair Value Estimate
Premium
XNAS:SGNT (): Consider Buying
Premium
XNAS:SGNT (): Consider Selling
Premium
XNAS:SGNT (): Fair Value Uncertainty
Premium
XNAS:SGNT (): Economic Moat
Premium
XNAS:SGNT (): Stewardship
Premium
 
FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Yu Chen-Ming
2. Date of Event Requiring Statement (Month/Day/Year)
08/30/2012
3. Issuer Name and Ticker or Trading Symbol
Sagent Pharmaceuticals, Inc. [SGNT]
(Last)
(First)
(Middle)
C/O SAGENT PHARMACEUTICALS, INC., 1901 NORTH ROSELLE ROAD, SUITE 700
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Interim COO
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)

SCHAUMBURG, IL 60195
6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock 1,000
D
 
Common Stock 8,961,452
I
See Footnote(1)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(Month/Day/Year)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option to Buy   (2) 08/15/2018 Common Stock 12,758 $4.23 D  
Restricted Stock Units   (3)   (4) Common Stock 2,268 (5) D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Yu Chen-Ming
C/O SAGENT PHARMACEUTICALS, INC.
1901 NORTH ROSELLE ROAD, SUITE 700
SCHAUMBURG, IL 60195
      Interim COO  

Signatures

/s/ Chen-Ming Yu 09/11/2012
** Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) The shares reported are held of record collectively by Vivo Ventures Fund V, L.P., Vivo Ventures V Affiliates Fund, L.P., Vivo Ventures Fund VI, L.P. and Vivo Ventures VI Affiliates Fund, L.P. (the "Vivo Funds"). Dr. Yu is a partner of Vivo Ventures. As a result, Dr. Yu may be deemed the beneficial owner of the shares of common stock owned collectively by the Vivo Funds. Dr. Yu hereby disclaims any beneficial ownership of any shares directly held by the Vivo Funds, except to the extent of his pecuniary interest therein.
(2) Stock option granted on August 15, 2008 and vests 25% per year over four years.
(3) The restricted stock units vest in four equal annual installments beginning on February 22, 2013. Vested shares will generally be delivered to the reporting person within 30 days following the vesting date.
(4) The restricted stock units vest in four equal annual installments beginning on February 22, 2013. Vested shares will generally be delivered to the reporting person within 30 days following the vesting date.
(5) Each restricted stock unit represents a contingent right to receive one share of SGNT common stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

XNAS:SGNT Sagent Pharmaceuticals Co Insider Activity 3 Filling

Sagent Pharmaceuticals Co XNAS:SGNT Stock - Get Insider Activity SEC Filing of Sagent Pharmaceuticals Co XNAS:SGNT stocks, including company profile, shares outstanding, strategy, business segments, operations, officers, consolidated financial statements, financial notes and ownership information.

XNAS:SGNT Insider Activity 3 Filing - 8/30/2012
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Title |  Date |  Company |  Symbol |  Interest |  Popularity

Previous: XNAS:SGNT Insider Activity 3 Filing - 3/7/2012  |  Next: XNAS:SGNT Insider Activity 4 Filing - 1/11/2012